EDMONTON, May 31, 2011 /PRNewswire/ - Compass Biotechnologies (COBI:OB) is pleased to announce that Dr. Joseph Sinkule President and COO of Compass Biotech has been invited to speak at the fourth annual World Generic Medicines Congress Americas 2011 to be held this fall from November 12 - November 15 at the Westin Grand, Washington D.C.
The Congress is the largest of its kind within the Generics Industry and for the first time this year is expanding to include the World Biosimiliars Summit to help focus on the key challenges facing the commercialization of the soon to be multiple billion dollar biosimiliar US and global markets.
The meeting unites a speaker platform of the highest seniority with all stakeholders in the industry and allows participants to position their products and services in front of decision makers from major Pharma manufacturers and large biotech companies. Dr. Sinkule who will speak on "Strategies and Opportunities for Smaller and Niche Generic Companies"
Dr Sinkule commented "It is indeed an honour and a privilege to be invited to speak at such a timely and prestigious event that will provide excellent exposure for the Company. Further, we feel it speaks to the acceptance of our approach to this increasingly important and growing market sector".
ABOUT COMPASS BIOTECHNOLOGIES INC. (COBI:OB) www.compassbio.net
Compass Biotechnologies is a publically-traded specialty
biopharmaceutical company (COBI:OB) with headquarters in Edmonton,
Alberta. The mission of Compass is to develop generic, biosimiliar and
bio-better drug products that can bring revenue generation to the
company in a near term fashion. A recent agreement with PanGen to
supply protein active pharmaceutical ingredients to facilitate this
mission was announced recently. Further Compass under a license from
the National Institutes of Health (NIH) has opportunities to develop
products from the platform technology available and or sub licensee
these opportunities to other interested partners. Compass Biotech also
owns a subsidiary company called C-Pharma Inc.
ABOUT C-PHARMA INC. www.c-pharma.net
C-Pharma's technology encompasses the use of recombinant DNA technology
to manufacture virus like particles (VLPs). These VLPs can be
engineered to incorporate various viral and non-viral antigens for use
as vaccines against many different types of targets such as Hepatitis
C. The recombinant antigens presented in the context of a VLP carrier
system are much more immunogenic than the antigen alone, and this
carrier is so powerful that the subsequent vaccine may not require the
use of immune adjuvants. C-Pharma is using the technology to develop a
Hepatitis C vaccine to prevent hepatitis C viral infection of liver
hepatocytes. The Company is also pursuing a revenue generation strategy
by commercializing generic therapeutic drugs (ribavirin and interferon
alpha) for use in the Hepatitis C market.
Forward Looking Statements
This news release contains "forward-looking statements", as that term is
defined in Section 27A of the United States Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Statements in this
current report which are not purely historical are forward-looking
statements and include any statements regarding beliefs, plans,
expectations or intentions regarding the future. Actual results could
differ from those projected in any forward-looking statements due to
numerous factors. Such factors include, among others, the inherent
uncertainty of financial estimates and projections, the competitive and
regulatory environments, stock market conditions, unforeseen technical
difficulties and our ongoing ability to operate a business and obtain
financing. These forward-looking statements are made as of the date of
this news release, and we assume no obligation to update the
forward-looking statements, or to update the reasons why actual results
could differ from those projected in the forward-looking statements.
Although we believe that our beliefs, plans, expectations and
intentions contained in this current report are reasonable, there can
be no assurance that such beliefs, plans, expectations or intentions
will prove to be accurate. Investors should consult all of the
information set forth herein and should also refer to the risk factors
disclosure outlined in our quarterly reports on Form 10-Q and our other
periodic reports filed from time-to-time with the Securities and
Exchange Commission pursuant to the Securities Exchange Act. For
further information and inquiries:
SOURCE Compass Biotechnologies Inc.
